Breaking down the cellular responses to type I interferon neurotoxicity in the brain

被引:20
作者
Viengkhou, Barney
Hofer, Markus J. [1 ]
机构
[1] Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
英国医学研究理事会;
关键词
type I interferons; cerebral interferonopathies; neurotoxin; neurodegenerative diseases; aging; multiple sclerosis; Aicardi-Goutieres syndrome; traumatic brain injury; AICARDI-GOUTIERES-SYNDROME; CENTRAL-NERVOUS-SYSTEM; ALPHA-INDUCED CHANGES; CHRONIC HEPATITIS-C; MULTIPLE-SCLEROSIS; IFN-ALPHA; NEUROLOGICAL DISEASE; INTRACRANIAL CALCIFICATION; THROMBOTIC MICROANGIOPATHY; MICROGLIA ACTIVATION;
D O I
10.3389/fimmu.2023.1110593
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Since their original discovery, type I interferons (IFN-Is) have been closely associated with antiviral immune responses. However, their biological functions go far beyond this role, with balanced IFN-I activity being critical to maintain cellular and tissue homeostasis. Recent findings have uncovered a darker side of IFN-Is whereby chronically elevated levels induce devastating neuroinflammatory and neurodegenerative pathologies. The underlying causes of these 'interferonopathies' are diverse and include monogenetic syndromes, autoimmune disorders, as well as chronic infections. The prominent involvement of the CNS in these disorders indicates a particular susceptibility of brain cells to IFN-I toxicity. Here we will discuss the current knowledge of how IFN-Is mediate neurotoxicity in the brain by analyzing the cell-type specific responses to IFN-Is in the CNS, and secondly, by exploring the spectrum of neurological disorders arising from increased IFN-Is. Understanding the nature of IFN-I neurotoxicity is a crucial and fundamental step towards development of new therapeutic strategies for interferonopathies.
引用
收藏
页数:14
相关论文
共 230 条
[21]   Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system [J].
Bonaccorso, S ;
Marino, V ;
Puzella, A ;
Pasquini, M ;
Biondi, M ;
Artini, M ;
Almerighi, C ;
Verkerk, R ;
Meltzer, H ;
Maes, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (01) :86-90
[22]   Interferons at age 50: past, current and future impact on biomedicine [J].
Borden, Ernest C. ;
Sen, Ganes C. ;
Uze, Gilles ;
Silverman, Robert H. ;
Ransohoff, Richard M. ;
Foster, Graham R. ;
Stark, George R. .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :975-990
[23]   Interferon-Alpha Reduces Human Hippocampal Neurogenesis and Increases Apoptosis via Activation of Distinct STAT1-Dependent Mechanisms [J].
Borsini, Alessandra ;
Cattaneo, Annamaria ;
Malpighi, Chiara ;
Thuret, Sandrine ;
Harrison, Neil A. ;
Zunszain, Patricia A. ;
Pariante, Carmine M. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2018, 21 (02) :187-200
[24]   Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults [J].
Bowman, Gene L. ;
Dayon, Loic ;
Kirkland, Richard ;
Wojcik, Jerome ;
Peyratout, Gwendoline ;
Severin, India C. ;
Henry, Hugues ;
Oikonomidi, Aikaterini ;
Migliavacca, Eugenia ;
Bacher, Michael ;
Popp, Julius .
ALZHEIMERS & DEMENTIA, 2018, 14 (12) :1640-1650
[25]   Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice [J].
Braun, D ;
Geraldes, P ;
Demengeot, J .
JOURNAL OF AUTOIMMUNITY, 2003, 20 (01) :15-25
[26]   Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency [J].
Briand, Coralie ;
Fremond, Marie-Louise ;
Bessis, Didier ;
Carbasse, Aurelia ;
Rice, Gillian I. ;
Bondet, Vincent ;
Duffy, Darragh ;
Chatenoud, Lucienne ;
Blanche, Stephane ;
Crow, Yanick J. ;
Neven, Benedicte .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (03) :431-+
[27]   Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion [J].
Broggi, Achille ;
Granucci, Francesca ;
Zanoni, Ivan .
JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 217 (01)
[28]   Structural and functional neuropathology in transgenic mice with CNS expression of IFN-α [J].
Campbell, IL ;
Krucker, T ;
Steffensen, S ;
Akwa, Y ;
Powell, HC ;
Lane, TC ;
Carr, DJ ;
Gold, LH ;
Henriksen, SJ ;
Siggins, GR .
BRAIN RESEARCH, 1999, 835 (01) :46-61
[29]   Interferon-alpha-induced changes in tryptophan metabolism: Relationship to depression and paroxetine treatment [J].
Capuron, L ;
Neurauter, G ;
Musselman, DL ;
Lawson, DH ;
Nemeroff, CB ;
Fuchs, D ;
Miller, AH .
BIOLOGICAL PSYCHIATRY, 2003, 54 (09) :906-914
[30]   Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy [J].
Capuron, L ;
Ravaud, A ;
Neveu, PJ ;
Miller, AH ;
Maes, M ;
Dantzer, R .
MOLECULAR PSYCHIATRY, 2002, 7 (05) :468-473